Results 21 to 30 of about 535,314 (143)
Radiation Macular Edema after Ru-106 Plaque Brachytherapy for Choroidal Melanoma Resolved by an Intravitreal Dexamethasone 0.7-mg Implant [PDF]
Case Reports in Ophthalmology, 2012 Purpose: To report the effective treatment of radiation macular edema following ruthenium-106 plaque brachytherapy for a choroidal melanoma with a dexamethasone 0.7-mg (Ozurdex®) intravitreal implant.
Andrea Russo +12 more
doaj +2 more sources
Indian Journal of Ophthalmology. Case Reports, 2023 Ozurdex® (Allergan, Inc., Irvine, CA, USA) is an intravitreal sustained-release drug delivery system containing dexamethasone, mainly used for the treatment of macular edema in diabetes, retinal vein occlusions or treatment of non-infectious posterior ...
Bristi Majumdar +9 more
doaj +2 more sources
Therapeutic delivery, 2019 Macular edema (ME) is the leading cause of visual loss in uveitis and may persist long after ocular inflammation has been resolved. Local steroids are the first line treatment for uveitis and uveitic ME.
H. Massa, P. Georgoudis, G. Panos
semanticscholar +2 more sources
Case Reports in Ophthalmology, 2011 Purpose: To report the effective treatment of cystoid macular edema (CME) following complicated cataract surgery (resulting in Irvine-Gass syndrome) with a dexamethasone 0.7-mg (Ozurdex®) intravitreal implant.
Linda M. Meyer, Carl-Ludwig Schönfeld
doaj +2 more sources
Journal of Ophthalmology, 2020 Purpose. The purpose of the study was to assess the efficacy of intravitreal dexamethasone implant (IDI: Ozurdex®) injection in eyes with macular edema due to retinal vein occlusion. Material and Method. A retrospective, nonrandomized study was conducted
Cristina Nicula +4 more
doaj +2 more sources
Intracrystalline Ozurdex®: therapeutic effect maintained for 18 months
International ophtalmology, 2017 Introduction: Ozurdex is a sterile, sustained-release implant of dexamethasone. The device dissolves within the vitreous body and releases dexamethasone. Here we present a clinical case that demonstrates the sustained therapeutic efficacy of Ozurdex when
R. Clemente-Tomás +6 more
semanticscholar +2 more sources
The nomadic Ozurdex®: Anterior migration of the dexamethasone implant and back! [PDF]
Oman Journal of Ophthalmology, 2017 Dexamethasone intravitreal implantation has been used in various retinal and uveal pathologies. Common complications include cataract formation and raised intraocular pressure. Although uncommon, migration of the implant has also been well reported.
Priya Srinivasan +2 more
doaj +2 more sources
European Journal of Ophthalmology, 2017 Purpose To evaluate the efficacy and safety of intravitreal 0.7-mg dexamethasone implant (DEX-I) (Ozurdex®) in the treatment of extensive exudative retinal detachment (RD) associated with uveal melanoma treated using proton beam therapy (PBT).
A. Malclès +4 more
semanticscholar +2 more sources
Results of intravitreal dexamethasone implant 0.7 mg (Ozurdex®) in non-infectious posterior uveitis [PDF]
International Journal of Ophthalmology, 2015 AIM:To evaluate the safety and efficacy of dexamethasone implant in patients with non-infectious posterior uveitis withcystoid macular edema (CME).METHODS:Retrospective analysis of patients reports with CME secondary to non-infectious uveitis treated ...
Yew Chong Yap +2 more
doaj +2 more sources
Repeated Treatment for Macular Edema in Vein Occlusion by Intravitreal Implant of Dexamethasone
Case Reports in Ophthalmology, 2012 Background: Macular edema (ME) treatment has benefited from the recent intravitreal pharmacotherapy development of an intravitreal implant of dexamethasone (Ozurdex®, Allergan, Irvine, Calif., USA).
Frederic Matonti +3 more
doaj +2 more sources